Updated Oct 15
To Booster or Not: Scientists and Regulators Debate
To Booster or Not: Scientists and Regulators Debate
President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.
To Booster or Not: Scientists and Regulators Debate
To Booster or Not: Scientists and Regulators Debate

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

President Biden’s planned rollout of additional COVID-19 vaccine doses is set to begin next week, but questions remain about who should get them.

Neutralizing antibody
COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research
Claire Jarvis | May 19, 2020
A blood biobank allows scientists to study the immune responses to the coronavirus among infected Biogen employees and their contacts.
Dengue Infection Impairs Immune Defense Against Zika
Dengue Infection Impairs Immune Defense Against Zika
Catherine Offord | Aug 18, 2017
A memory B cell response to Zika virus in dengue-infected patients produced antibodies that were poorly neutralizing in vitro and instead enhanced infection.
Unique Antibodies Open Path Toward New HIV Vaccines
Unique Antibodies Open Path Toward New HIV Vaccines
Amanda B. Keener | Jan 27, 2017
A family of broadly neutralizing antibodies from a chronically infected donor provides a schematic for designing vaccines and treatments that target multiple strains of the virus.
Culprit for Antibody Blockade Identified
Culprit for Antibody Blockade Identified
Amanda B. Keener | Oct 21, 2016
Type I interferon organizes several immune mechanisms to suppress B cell responses to a chronic viral infection.
Accelerating Antibody Discovery
Accelerating Antibody Discovery
Nicholette Zeliadt | May 1, 2014
Techniques for faster discovery and isolation of human monoclonal antibodies